Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02646475 · ClinicalTrials.gov registry record · Phase 1
Metabolic Effects of Angiotensin-(1-7)
A Phase 1 study of Obesity and Hypertension, sponsored by Vanderbilt University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02646475 is a Phase 1 study of Obesity and Hypertension that is actively recruiting participants, run by Vanderbilt University. The registered enrollment target is 26 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02646475, a Phase 1 study of Obesity and Hypertension, is actively recruiting participants, sponsored by Vanderbilt University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies. It is unclear if this peptide contributes to the regulation of metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance. The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.
Conditions Studied
Interventions
- DRUG Saline
- DRUG Angiotensin-(1-7)
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-02 |
| Est. Completion | 2029-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02646475
The ClinicalTrials.gov registry entry for NCT02646475 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT02646475 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT02646475 about?
NCT02646475 is a clinical study titled "Metabolic Effects of Angiotensin-(1-7)". The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related dis...
What is the current status of trial NCT02646475?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2016-02. Estimated completion is 2029-12.
What conditions does trial NCT02646475 study?
This clinical trial studies the following conditions: Obesity, Hypertension, Insulin Resistance, Metabolic Cardiovascular Syndrome.
What interventions are being tested in trial NCT02646475?
The interventions under investigation include: Saline (DRUG), Angiotensin-(1-7) (DRUG).
Who is sponsoring clinical trial NCT02646475?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02646475 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Mechanisms of Semaglutide Therapy in Heart Failure Patients
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.